Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Morschhauser, Franck; Dahiya, Saurabh; Lia Palomba, M.; Martı́n, Alejandro; Luis Reguera Ortega, Juan; Kuruvilla, John; Jäger, Ulrich; Cartron, Guillaume; Izutsu, Koji; Dreyling, Martin; S. Kahl, Brad; Ghesquières, Hervé; M. Ardeshna, Kirit; Goto, Hideki; Maria Barbui, Anna; S. Abramson, Jeremy; Borchmann, Peter; Fleury, Isabelle; Mielke, Stephan; P Skarbnik, Alan; de Vos, Sven; Kamdar, Manali; Karmali, Reem; Viardot, Andreas; A. Farazi, Thalia; Fasan, Omotayo; Lymp, James; Vedal, Min; Nishii, Rina; Avilion, Ariel; Papuga, Jessica; Kumar, Jinender; J. Nastoupil, Loretta

doi:10.1038/s41591-024-02986-9

Public

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Published in Nature Medicine • Jun 3, 2024

Authors:

Franck Morschhauser

Saurabh Dahiya

M. Lia Palomba

Abstract

An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24 months (POD24) from first-line immunochemotherapy or disease refractory to both CD20-targeting agent and alkylator (double refractory), d...

Subject

Medicine

Follicular lymphoma

Refractory (planetary science)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!